Celldex Therapeutics
Celldex Therapeutics is a clinical stage biotechnology company focused on developing antibody-based therapeutics for inflammation and oncology, with lead programs including barzolvolimab and CDX-585.
Company Overview
Celldex Therapeutics is a clinical stage biotechnology company that focuses on the development of antibody-based therapeutics. Their operations span multiple locations, including Hampton, NJ; New Haven, CT; Fall River, MA; and Needham, MA. Celldex's proprietary antibody programs benefit from robust in-house capabilities optimized for discovery and development. The company is dedicated to addressing significant medical needs and providing treatment options for patients with severe conditions.
Therapeutic Focus Areas
Celldex Therapeutics is primarily engaged in developing treatments for inflammation and oncology. Specific conditions targeted by their therapeutics include chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. The company aims to provide solutions for patient populations with significant medical needs and limited treatment options, leveraging their advanced antibody-based technologies.
Lead Program: Barzolvolimab
Celldex's lead program is barzolvolimab, a humanized monoclonal antibody inhibitor of KIT. This therapeutic targets mast cells, which are critical in severe inflammatory, allergic, and autoimmune diseases. Barzolvolimab is under development for various conditions, including chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. It is anticipated to enter Phase 3 trials for chronic spontaneous urticaria in summer 2024.
Pipeline and Development Programs
Celldex is developing a bispecific antibody platform for next-generation treatments in inflammation and oncology. One of the key candidates, CDX-585, is a bispecific antibody combining PD-1 blockade and anti-ILT4 blockade, aimed at treating solid tumors. CDX-585 is currently completing CMC and IND-enabling activities and is expected to enter clinical trials in 2023. Celldex's development programs are designed to cater to patient populations with severe conditions and few treatment alternatives.
Compassionate Use and Expanded Access Program
Celldex Therapeutics offers a Compassionate Use or Expanded Access Program for patients with life-threatening diseases who have exhausted other treatment options. This program allows patients access to investigational drugs outside of clinical trials, demonstrating Celldex's commitment to addressing the needs of patients with limited therapeutic alternatives.